FDA EIR - Gemini Pharmaceuticals, Inc. - February 05, 2009

An FDA inspection of Gemini Pharmaceuticals, Inc. in Commack, NY, was conducted on February 4-5, 2009. The inspection aimed to assess compliance with Good Manufacturing Practices (CGMP) for both human and animal over-the-counter (OTC) drug manufacturing, specifically focusing on Phenylpropanolamine HCL (animal) and Phenylephrine HCL (human) drugs, under regulatory guidelines CP 7356.002 and 7371.001.

This inspection followed a previous one on November 27, 2007, which, despite a "No Action Indicated" classification, had identified several deficiencies. These included inadequate Standard Operating Procedures (SOPs) for Out-of-Specification (OOS) test results, insufficient investigations into content uniformity failures, non-comprehensive annual product reviews, unrepresentative blending validation samples, and incomplete labeling SOPs regarding product information verification during packaging.

Significantly, the current inspection revealed that Gemini Pharmaceuticals, Inc. had voluntarily corrected all previously identified drug CGMP deficiencies. During this two-day review of the firm's facility, equipment, materials, and product systems, no new drug CGMP violations were observed, and consequently, no FDA-483 was issued. No samples were collected, indicating a positive outcome for the company regarding compliance at the time of this inspection.